I am neither long nor short on AVIR.
My opinion is most Shorts have covered by now, took their huge profits home. The only way the stock goes higher is if it gets positive news from its other clinical trials. However if those trials turn out negative also, this stock could go to 7 in a hurry.
The company has cash, but trials are very expensive and will burn it easily. The only significant revenue it had was an infusion of $60 mil from Roche just recently. With today's bad clinical outcome, I don't expect additional money from Roche for a while .
Best wishes to all.$Atea Pharmaceuticals, Inc.(AVIR)$
精彩评论